Key facts
- This page summarizes Jeffrey B. Mirviss Power's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jan 2025, 16:32.
Jeffrey B. Mirviss Power - 01 Jan 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)
- Reporting relationship
- EVP&Pres, Periph Intervent
- Issuer ticker
- BSX
- Reported as of
- 01 Jan 2025
- Net transaction value
- -$935,449
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2025, 16:32:57 UTC
- Prior SEC filing
- 30 May 2024
- Next SEC filing
- 13 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Susan Thompson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey B. Mirviss Power filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 03 Jan 2025.
Change
- Previous filing in this sequence was filed on 30 May 2024.
- Current net transaction value: -$935,449.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BSX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +10,430
- Change %
- +37%
- Price
- $0.000000
- Shares after
- 38,884
- Date
- 01 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
BSX
transaction
Common Stock
Tax liability
- Transaction value
- $292,791
- Shares
- -3,278
- Change %
- -8.4%
- Price
- $89.32
- Shares after
- 35,606
- Date
- 01 Jan 2025
- Ownership
- Direct
BSX
transaction
Common Stock
Sale
- Transaction value
- $642,658
- Shares
- -7,152
- Change %
- -20%
- Price
- $89.86
- Shares after
- 28,454
- Date
- 03 Jan 2025
- Ownership
- Direct
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BSX
transaction
Derivative
Performance Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -10,430
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,430
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
Footnote F2
Includes shares acquired on June 30, 2024 under the Company's Employee Stock Purchase Plan based upon the most current data available.
Footnote F3
The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.
Footnote F4
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.523 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F5
Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.